Press Releases News / Events Overview Press Releases In The News IR Calendar Email Alerts Year All Years 2021 2020 2019 Category All Releases Financial Releases NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021 Feb 11, 2021 4:01pm EST NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics Jan 28, 2021 8:00am EST NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference Jan 11, 2021 6:00am EST NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020 Dec 23, 2020 4:05pm EST NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL™-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1 Dec 16, 2020 6:30am EST NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer Dec 02, 2020 8:00am EST NeuBase Therapeutics to Participate in Upcoming Investor Conferences Nov 23, 2020 8:00am EST NeuBase Therapeutics Announces Addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to Scientific Advisory Board Nov 17, 2020 8:00am EST NeuBase Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 Nov 10, 2020 8:00am EST NeuBase Therapeutics' CEO, Dietrich A. Stephan, Ph.D., to Present "Manufacturing Heat-Seeking Missiles Against Misbehaving Genes" at Tribe Public's Event on October 28, 2020 Oct 26, 2020 8:15am EDT 1 2 3 4 5 Next
NeuBase Therapeutics Reports Financial Results for the First Quarter of Fiscal Year 2021 Feb 11, 2021 4:01pm EST
NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics Jan 28, 2021 8:00am EST
NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference Jan 11, 2021 6:00am EST
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020 Dec 23, 2020 4:05pm EST
NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL™-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1 Dec 16, 2020 6:30am EST
NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer Dec 02, 2020 8:00am EST
NeuBase Therapeutics Announces Addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to Scientific Advisory Board Nov 17, 2020 8:00am EST
NeuBase Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 Nov 10, 2020 8:00am EST
NeuBase Therapeutics' CEO, Dietrich A. Stephan, Ph.D., to Present "Manufacturing Heat-Seeking Missiles Against Misbehaving Genes" at Tribe Public's Event on October 28, 2020 Oct 26, 2020 8:15am EDT
